Literature DB >> 11738946

Myelodysplastic syndrome: review of the cytogenetic and molecular data.

P Mhawech1, A Saleem.   

Abstract

Myelodysplastic syndrome (MDS) is a monoclonal disorder of the pluripotent stem cell that frequently evolves into acute leukemia. MDS is characterized by trilineage dysplasia and by ineffective hematopoiesis. The etiology of MDS is poorly understood. However, the frequent association of chromosomal abnormalities (deletions, inversions, translocations, trisomies and monosomies) with MDS suggests that an oncogene, or a tumor suppressor gene might be involved in the pathogenesis and evolution of this disorder. This review summarizes the clinical, laboratory, chromosomal and prognostic findings of some of the cytogenetic abnormalities such as; 20q deletion, chromosome 5, 7 and 3 abnormalities, 17p-syndrome, trisomy 8, and loss of Y chromosome. In addition, this review goes into the discussion of the most recent development in the field of molecular biology to understand some of the mechanisms resulting in the development and progression of MDS.

Entities:  

Mesh:

Year:  2001        PMID: 11738946     DOI: 10.1016/s1040-8428(01)00101-9

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  Internuclear chromosome distribution of dysplastic megakaryocytes in myelodysplastic syndromes is dependent on the level of ploidy.

Authors:  Claudia Münch; Annette M May; Dieter Hauschke; Jasmine Roth; Silke Lassmann; Martin Werner
Journal:  Chromosoma       Date:  2011-02-01       Impact factor: 4.316

2.  Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome.

Authors:  Xiao Li; C Eileen Bryant; H Joachim Deeg
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

3.  Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Authors:  Hideki Nakasone; Mats Remberger; Lu Tian; Petter Brodin; Bita Sahaf; Fang Wu; Jonas Mattsson; Robert Lowsky; Robert Negrin; David B Miklos; Everett Meyer
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

4.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

5.  Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy.

Authors:  Takahiro Yamauchi; Haruhisa Shirasaki; Atsushi Kuwata; Taro Yamashita; Shin Imamura; Hiroshi Tsutani; Takanori Ueda
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

6.  Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.

Authors:  Yasuyoshi Morita; Akihisa Kanamaru; Yasushi Miyazaki; Daisuke Imanishi; Fumiharu Yagasaki; Mitsune Tanimoto; Kazutaka Kuriyama; Toru Kobayashi; Shion Imoto; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

Review 7.  Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

Authors:  Sebastian Stintzing; Ralf Kemmerling; Tobias Kiesslich; Beate Alinger; Matthias Ocker; Daniel Neureiter
Journal:  J Biomed Biotechnol       Date:  2011-05-15

8.  Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

Authors:  Yasser Elnahass; Lamiaa Youssif
Journal:  J Adv Res       Date:  2018-02-07       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.